Get the Stockscreener App
103.00
1.40%
-1.46
After Hours:
105.47
2.47
+2.40%
Axsome Therapeutics Inc stock is traded at $103.00, with a volume of 661.18K.
It is down -1.40% in the last 24 hours and down -18.76% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$104.46
Open:
$103.55
24h Volume:
661.18K
Relative Volume:
0.75
Market Cap:
$5.05B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-15.77
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-0.51%
1M Performance:
-18.76%
6M Performance:
+12.57%
1Y Performance:
+51.69%
1-Day Range:
$101.58
$104.17
1-Week Range:
$101.32
$105.66
52-Week Range:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
103.00 | 5.05B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Russell Investments Group Ltd. Boosts Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Leerink Partnrs Brokers Increase Earnings Estimates for AXSM - MarketBeat
Leerink Partnrs Has Pessimistic Outlook of AXSM Q1 Earnings - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Holdings Lowered by Affinity Asset Advisors LLC - MarketBeat
Axsome slips as late-stage trial for depression therapy fails - MSN
1492 Capital Management LLC Purchases New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
LPL Financial LLC Buys 7,837 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Kennedy Capital Management LLC Raises Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
91,649 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Granite Investment Partners LLC - MarketBeat
Invesco Ltd. Increases Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Reduced by Alliancebernstein L.P. - MarketBeat
XTX Topco Ltd Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Geode Capital Management LLC Raises Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Trexquant Investment LP Acquires New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
This Little-Known Stock Could Be One of the Best Recession-Proof Investments Now - The Globe and Mail
Is Axsome Therapeutics (NASDAQ:AXSM) A Risky Investment? - simplywall.st
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm - Kilgore News Herald
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO - GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT) Should Contact Grabar Law Office Today - GlobeNewswire Inc.
Zacks Research Analysts Decrease Earnings Estimates for AXSM - MarketBeat
What is Zacks Research's Forecast for AXSM FY2025 Earnings? - MarketBeat
American Century Companies Inc. Invests $570,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 6.9%What's Next? - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Position Raised by ADAR1 Capital Management LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Franklin Resources Inc. Purchases 21,756 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands - Bluefield Daily Telegraph
Attention Long-Term Shareholders of Axsome Therapeutics, - GlobeNewswire
Schroder Investment Management Group Sells 34,158 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? - Yahoo Finance
Axsome (AXSM) Reports Positive Phase 3 Results for ADHD Treatmen - GuruFocus
Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy - Yahoo Finance
Norges Bank Purchases Shares of 403,026 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Wellington Management Group LLP Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
AAN 2025: Axsome Therapeutics’ treatment for Alzheimer’s agitation shows promise - Yahoo
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to C - GuruFocus
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics - Bluefield Daily Telegraph
ALERT: Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 - The Manila Times
Axsome Earnings Alert: CNS Drug Leader Sets Q1 2025 Results Date - Stock Titan
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Option Exercise |
3.50 |
3,000 |
10,500 |
45,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 13 '25 |
Sale |
129.86 |
12,000 |
1,558,320 |
42,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Sale |
131.07 |
3,000 |
393,210 |
42,187 |
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):